Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias
AssigneesBrainvectis, Inserm (Institut National De La Sante Et De La Recherche Medicale), Universidade De Coimbra, Centro de Neurociencias e Biologia Celular
InventorsSandro ALVES, Nathalie CARTIER-LACAVE, Luis PEREIRA DE ALMEIDA, Clévio NOBREGA, Liliana MENDONÇA
Life of this patent
Estimating the term…
Abstract
The present invention relates to a vector for use in the treatment of a polyglutamine repeat spinocerebellar ataxia, which vector comprises cholesterol 24-hydroxylase encoding nucleic acid.
Claims21
-20. (canceled)
A vector for treating a Polyglutamine repeat spinocerebellar ataxia, which vector comprises cholesterol 24-hydroxylase encoding nucleic acid.
A vector for use in the treatment of a Polyglutamine repeat spinocerebellar ataxia, which vector comprises cholesterol 24-hydroxylase encoding nucleic acid.
(canceled)
(canceled)
The vector for use in the treatment of a Polyglutamine repeat spinocerebellar ataxia according to claim 39, which is to be administered to cerebellum, brainstem, substantia nigra, striatum, frontotemporal lobes and/or visual cortex, preferably to cerebellum.
Dependencies are inferred from the claim text.